References
- RossRThe pathogenesis of atherosclerosis – an updateN Engl J Med19863144885003511384
- LibbyPInflammation in atherosclerosisNature200242086887412490960
- TedguiAMallatZCytokines in atherosclerosis: pathogenic and regulatory pathwaysPhysiol Rev20068651558116601268
- LoppnowHWerdanKBuerkeMVascular cells contribute to atherosclerosis by cytokine- and innate-immunity-related inflammatory mechanismsInnate Immun200814638718713724
- SunJSukhovaGKWoltersPJMast cells promote atherosclerosis by releasing proinflammatory cytokinesNat Med20071371972417546038
- HanssonGKHolmJJonassonLDetection of activated T lymphocytes in the human atherosclerotic plaqueAm J Pathol19891351691752505620
- BlankenbergSBarbauxSTiretLAdhesion molecules and atherosclerosisAtherosclerosis200317019120314612198
- LusterADChemokines-chemotactic cytokines that mediate inflammationN Engl J Med19983384364459459648
- GersztenREMachFSautyARosenzweigALusterADChemokines, leukocytes, and atherosclerosisJ Lab Clin Med2000136879210945236
- BazanJFBaconKBHardimanGFractalkine: a new class of membrane-bound chemokine with CX3C motifNature199738564448985246
- ImaiTHieshimaKHaskellCIdentification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesionCell1997915215309390561
- HarrisonJKJiangYWeesEAInflammatory agents regulate in vivo expression of fractalkine in endothelial cells of the rat heartJ Leukoc Biol19996693794410614775
- ChapmanGAMooresKEGohilJThe role of fractalkine in the recruitment of monocytes to the endotheliumEur J Pharmacol200039218919510762673
- LudwigABerkhoutTMooresKGrootPChapmanGFractalkine is expressed by smooth muscle cells in response to IFN-gamma and TNF-alpha and is modulated by metalloproteinase activityJ Immunol200216860461211777952
- WongBWWongDMcManusBMCharacterization of fractalkine (CX3CL1) and CX3CR1 in human coronary arteries with native atherosclerosis, diabetes mellitus, and transplant vascular diseaseCardiovasc Pathol20021133233812459434
- HundhausenCMisztelaDBerkhoutTAThe disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesionBlood20031021186119512714508
- HaskellCAClearyMDCharoIFMolecular uncoupling of fractalkine-mediated cell adhesion and signal transduction. Rapid flow arrest of CX3CR1-expressing cells is independent of G-protein activationJ Biol Chem1999274100531005810187784
- MichelsenKSDohertyTMShahPKArditiMTLR signaling: An emerging bridge from innate immunity to atherogenesisJ Immunol20041735901590715528321
- RobinsonLANatarajCThomasDWA role for fractalkine and its receptor (CX3CR1) in cardiac allograft rejectionJ Immunol20001656067607211086038
- KimTSLimHKLeeJYChanges in the levels of plasma soluble fractalkine in patients with mild cognitive impairment and Alzheimer’s diseaseNeurosci Lett200843619620018378084
- BjerkeliVDamasJKFevangBHolterJCAukrustPFrolandSSIncreased expression of fractalkine (CX3CL1) and its receptor, CX3CR1, in Wegener’s granulomatosis--possible role in vascular inflammationRheumatology2007461422142717616549
- DamåsJKBoullierAWaehreTExpression of fractalkine (CX3CL1) and its receptor, CX3CR1, is elevated in coronary artery disease and is reduced during statin therapyArterioscler Thromb Vasc Biol2005252567257216224053
- McDermottDHHalcoxJPSchenkeWHAssociation between polymorphism in the chemokine receptor CX3CR1 and coronary vascular endothelial dysfunction and atherosclerosisCirc Res20018940140711532900
- MoattiDFaureSFumeronFPolymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery diseaseBlood2001971925192811264153
- SteinerGDiabetes and atherosclerosis: an overviewDiabetes198130Suppl 2177028539
- BasuADevarajSJialalIDietary factors that promote or retard inflammationArterioscler Thromb Vasc Biol200626995100116484595
- GravesDTLiuROatesTWDiabetes-enhanced inflammation and apoptosis: impact on periodontal pathosisPeriodontol 200020074512813717850453
- RusterCWolfGThe role of chemokines and chemokine receptors in diabetic nephropathyFront Biosci20081394495517981602
- AlipourAvan OostromAJIzraeljanALeukocyte activation by triglyceride-rich lipoproteinsArterioscler Thromb Vasc Biol20082879279718218988
- WantenGvan Emst-De VriesSNaberTWillemsPNutritional lipid emulsions modulate cellular signaling and activation of human neutrophilsJ Lipid Res20014242843611254755
- van OostromAJRabelinkTJVerseydenCActivation of leukocytes by postprandial lipemia in healthy volunteersAtherosclerosis200417717518215488881
- AlipourAElteJWvan ZaanenHCRietveldAPCabezasMCPostprandial inflammation and endothelial dysfunctionBiochem Soc Trans20073546646917511629
- NorataGDGrigoreLRaselliSPost-prandial endothelial dysfunction in hypertriglyceridemic subjects: molecular mechanisms and gene expression studiesAtherosclerosis200719332132717055512
- BermúdezBLópezSPachecoYMInfluence of postprandial triglyceride-rich lipoproteins on lipid-mediated gene expression in smooth muscle cells of the human coronary arteryCardiovasc Res20087929430318359786
- LoppnowHLibbyPProliferating or interleukin-1-activated human vascular smooth muscle cells secrete copious interleukin-6J Clin Invest1990857317382312724
- ChenLFristerAWangSInteraction of vascular smooth muscle cells and monocytes by soluble factors synergistically enhances interleukin-6 and MCP-1 productionAm J Physiol Heart Circ Physiol2009296987996
- BursillCAChannonKMGreavesDRThe role of chemokines in atherosclerosis: recent evidence from experimental models and population geneticsCurr Opin Lipidol20041514514915017357
- GhilardiGBiondiMLTurriOGuagnelliniEScorzaRInternal carotid artery occlusive disease and polymorphisms of fractalkine receptor CX3CR1: a genetic risk factorStroke2004351276127915118174
- FranklinBATrivaxJEVanheckeTENew insights in preventive cardiology and cardiac rehabilitationCurr Opin Cardiol20082347748618670260
- AlipourAElteJWvan ZaanenHCRietveldAPCastro CabezasMNovel aspects of postprandial lipemia in relation to atherosclerosisAtheroscler Suppl20089394418595782
- NissenSETuzcuEMSchoenhagenPStatin therapy, LDL cholesterol, C-reactive protein, and coronary artery diseaseN Engl J Med2005352293815635110
- PrasadKC-reactive protein-(CRP)-lowering agentsCardiovasc Drug Rev200624335016939632
- ApostolakisSKrambovitisEVlataZKochiadakisGEBaritakiSSpandidosDACX3CR1 receptor is up-regulated in monocytes of coronary artery diseased patients: impact of pre-inflammatory stimuli and renin-angiotensin system modulatorsThromb Res200712138739517521710
- AlbertMADanielsonERifaiNRidkerPMEffect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort studyJAMA2001286647011434828
- WuHPChenCHHsiehHCLiuYCEffects of insulin and glucose on cytokine production from peripheral blood mononuclear cellsChang Gung Med J20083125325918782947
- OkazakiMIwasakiYJingHInsulin enhancement of cytokine-induced coagulation/inflammation-related gene transcription in hepatocytesEndocr J20085596797518614853
- HusbergCNygårdSFinsenAVCytokine expression profiling of the myocardium reveals a role for CX3CL1 (fractalkine) in heart failureJ Mol Cell Cardiol20084526126918585734